

8025801-9093

For the use of a Registered Medical Practitioner
or a Hospital or a Laboratory only.

LOOKBRITE

(Hydroquinone 2% + Tretinoin 0.025%
+ Mometasone Furoate 0.1% Cream)

Composition :


Hydroquinone U.S.P.	2% w/w
Tretinoin U.S.P.	0.025% w/w
Mometasone Furoate I.P.	0.1% w/w
Preservatives :	
Methyl Paraben I.P.	0.18% w/w
Propyl Paraben I.P.	0.02% w/w
In a cream base	q.s.

Description :


The chemical name for Hydroquinone is 1,4-Benzenediol. Its molecular formula is $C_6H_6O_2$ and molecular weight is 110.11.



The chemical name for Tretinoin is Retinoic acid. Its molecular formula is $C_{20}H_{28}O_2$ and molecular weight is 300.44



The chemical name for Mometasone Furoate is 9 α , 21-Dichloro-11 β -hydroxy-16 α -methyl-3,20-dioxopregna-1, 4-dien-17-ylfuran-2- carboxylate. Its molecular formula is $C_{27}H_{30}Cl_2O_6$ and molecular weight is 521.4



Pharmacology :

Hydroquinone is classified therapeutically as a depigmentation agent. Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine and suppression of other melanocyte metabolic processes. Tretinoin is classified as keratolytic agent. Tretinoin is a retinoid metabolite of Vitamin A that binds to intracellular receptors in the cytosol and nucleus, but cutaneous levels of tretinoin in excess of physiologic concentrations occur following application of a tretinoin containing topical drug product. Mometasone furoate like other topical corticosteroids has anti-inflammatory, anti-pruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids in general is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.

The combined agents in Lookbrite act by inhibiting one or more steps in the tyrosine-tyrosinase pathway of melanin synthesis. It also affects the formation of melanization and degradation of melanosomes and eventually causes necrosis of the whole melanocytes. The hyperpigmented areas fade rapidly than the surrounding normal skin. A great majority (>80%) of patients with melasma may note some improvement in eight weeks.

Indication :

For short term intermittent treatment of moderate to severe melasma of the face in the presence of measures for sun avoidance including use of sun screen.

Contra-indications :

LOOKBRITE cream is contra-indicated in those patients with prior history of allergic reaction to hydroquinone, tretinoin and mometasone furoate.

Precautions and Warning :

The safety of LOOKBRITE cream during pregnancy and children (below 12 years) has not been established. Caution should be exercised when LOOKBRITE cream is administered to nursing mothers. LOOKBRITE cream is strictly for external use only. Avoid contact with eyes, mouth and mucous membranes. Exposure to sunlight or ultra-violet light will cause repigmentation of bleached areas.

Adverse Reactions :

The adverse reactions reported are dryness, fissuring of paranasal and infraorbital areas, erythema and stinging. Occasional hyper-sensitivity may develop. If this occurs, LOOKBRITE cream should be discontinued and the physician notified immediately.

Method of use :

LOOKBRITE cream should be applied preferably once daily, in the evening. Duration of application would be determined by the physician, depending on the response.

Expiry Date :

Do not use later than expiry date.

Storage :

Store in a dry place at a temperature not exceeding 25°C, protected from light. Do not freeze. Keep out of reach of children.

Keep tube tightly closed after use.

For external use only

Presentation

LOOKBRITE cream is available in a tube of 20 gm.



Marketed by :

TORRENT PHARMACEUTICALS LTD.
Indrad-382 721, Dist. Mehsana, INDIA.

Manufactured by :

Aurochem Laboratories (I) Pvt. Ltd.
8, Palghar Taluka Industrial Co-op. Estate Limited.
Palghar- 401 404, Dist. Thane. Maharashtra.